The effect of an oral anti-oxidant, N-Acetyl-cysteine, on inflammatory and oxidative markers in pulmonary sarcoidosis

Hamzeh, Nabeel; Li, Li; Barkes, Briana; Huang, Jie; Canono, Beth P.; Gillespie, May; Maier, Lisa A.; Day, Brian J.

doi:10.1016/j.rmed.2016.01.011

Cited by 11 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a mucolytic agent, NAC not only has the effect of directly dissolving mucus expectorant but also has the effect of anti-inflammatory, antioxidant, increasing the secretion and activity of active substances in the lung. [ 12 – 15 ] A large number of free radicals are produced in ARDS patients. Endogenous antioxidant substances may reduce the damage to target cells, lung interstitial fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19

et al. 2020

View full text Add to dashboard Cite

Rationale: The new coronavirus pneumonia Corona Virus Disease 2019 (COVID-19) has become a global pandemic. Patients with critically COVID-19 usually require invasive respiratory support, and the airway management is particularly important and the prognosis is poor. Patient concerns: A 64-year-old man with an anastomotic fistula after radical treatment of esophageal cancer and right-side encapsulated pyopneumothorax was admitted with cough and dyspnea. Diagnosis: The patient was diagnosed with novel coronavirus pneumonia and right-side encapsulated pyopneumothorax by pharyngeal swab nucleic acid test in combination with chest computed tomography (CT). Interventions: The patient was treated with antibiotics, antiviral and antibacterial medications, respiratory support, expectorant nebulization, and nutritional support. But he expressed progressive deterioration. Endotracheal intubation and mechanical ventilation were performed since the onset of the type - respiratory failure on the 13th day of admission. The patient had persistent refractory hypercapnia after mechanical ventilation. Based on the treatment mentioned above, combined with repeated bronchoalveolar lavage by using N-acetylcysteine (NAC) inhalation solution, the patients refractory hypercapnia was gradually improved. Outcomes: The patient was cured and discharged after being given the mechanical ventilation for 26 days as well as 46 days of hospitalization, currently is surviving well. Lessons : Patients with severe conditions of novel coronavirus pneumonia often encounter bacterial infection in their later illness-stages. They may suffer respiratory failure and refractory hypercapnia that is difficult to improve due to excessive mucus secretion leading to small airway obstruction. This study provided a new insight on the proper treatment severe COVID-19 patients. The use of reasonable antibiotics and symptomatic respiratory support and other treatment, timely artificial airway and repeated bronchoalveolar NAC inhalation solution lavage, expectorant and other airway management are essential for such patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As a mucolytic agent, NAC not only has the effect of directly dissolving mucus expectorant but also has the effect of anti-in ammatory, antioxidant, increasing the secretion and activity of active substances in the lung (12)(13)(14)(15). A large number of free radicals are produced in ARDS patients.…”

Section: Discussionmentioning

confidence: 99%

Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19

Liu¹,

Luo²,

Qian³

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Object: To report the successful diagnosis and treatment of a patient with critical condition of novel coronavirus pneumonia (COVID-19) and to summarize its clinical features and airway management experience in successful treatment.Methods: Retrospectively analyzed the successful management of one case of COVID-19 with critical condition combined respiratory failure and discussed the clinical characteristics and airway management of the patient in conjunction with a review of the latest literature.Results: A patient with an anastomotic fistula after radical treatment of esophageal cancer and right-side encapsulated pyopneumothorax was admitted with cough and dyspnea and was diagnosed with novel coronavirus pneumonia and malnutrition by pharyngeal swab nucleic acid test in combination with chest CT. The patient was treated with antibiotics, antiviral and antibacterial medications, respiratory support, expectorant nebulization, and nutritional support, expressed progressive deterioration. Endotracheal intubation and mechanical ventilation were performed since the onset of the type Ⅱ respiratory failure on the 13th day of admission. The patient had persistent refractory hypercapnia after mechanical ventilation. Based on the treatment mentioned above, combined with repeated bronchoalveolar lavage by using N-acetylcysteine (NAC) inhalation solution, the patient's refractory hypercapnia was gradually improved. It was cured and discharged after being given the mechanical ventilation for 26 days as well as 46 days of hospitalization, currently is surviving well.Conclusion: Patients with severe conditions of novel coronavirus pneumonia often encounter bacterial infection in their later illness-stages. They may suffer respiratory failure and refractory hypercapnia that is difficult to improve due to excessive mucus secretion leading to small airway obstruction. In addition to the use of reasonable antibiotics and symptomatic respiratory support and other treatment, timely artificial airway and repeated bronchoalveolar NAC inhalation solution lavage, expectorant and other airway management are essential for such patients.

show abstract

“…Results showed that NAC failed to suppress ex vivo TNF-α production from BAL cells despite effects in vitro, a discrepancy that the authors attributed to the poor pulmonary bioavailability of oral NAC in the lung tissue. Conversely, there was a 59% increase in BAL GSH levels after NAC treatment, an encouraging result that can still support the idea that antioxidant therapy may have a role in the management of sarcoidosis, although no clinical trials have yet followed up these findings [ 106 ].…”

Section: Antioxidant Interventions In Sarcoidosismentioning

confidence: 99%

The Role of Oxidative Stress in Sarcoidosis

Fois

Canu

Fois

2021

IJMS

View full text Add to dashboard Cite

Sarcoidosis is a rare, systemic inflammatory disease whose diagnosis and management can pose a challenge for clinicians and specialists. Scientific knowledge on the molecular pathways that drive its development is still lacking, with no standardized therapies available and insufficient strategies to predict patient outcome. In recent years, oxidative stress has been highlighted as an important factor in the pathogenesis of sarcoidosis, involving several enzymes and molecules in the mechanism of the disease. This review presents current data on the role of oxidative stress in sarcoidosis and its interaction with inflammation, as well as the application of antioxidative therapy in the disease.

show abstract

The effect of an oral anti-oxidant, N-Acetyl-cysteine, on inflammatory and oxidative markers in pulmonary sarcoidosis

Cited by 11 publications

References 23 publications

Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19

Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19

Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19

The Role of Oxidative Stress in Sarcoidosis

Contact Info

Product

Resources

About